Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
Developing small molecule and biologic therapeutics presents unique challenges at each development phase. This development requires the knowledge, experience, and a broad range of assays and reagents to understand the therapeutics' structure, activity, and mechanism of action (MOA). Eurofins DiscoverX® provides the most comprehensive portfolio of stable cell lines, validated functional and binding assay kits, recombinant proteins, and optimized reagents with these qualities developed and manufactured to support your drug discovery and development journey every step of the way. Several customized solutions can be delivered for program-specific needs by utilizing our deep expertise in cell line engineering, assay design, method qualification, and cell and protein production.
At Eurofins DiscoverX, we are committed to enabling and accelerating your multi-modality drug discovery and development programs from Discovery, through Development, and into Commercial Release & Stability. Discover for yourself how Eurofins DiscoverX enables you to accelerate your therapeutics development. Progress forward, confidently.
Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
The Eurofins DiscoverX portfolio of high-quality products and custom assays enables you to expedite your research, and move your candidate through the drug discovery pipeline faster.
Eurofins DiscoverX bioassays are fit-for-purpose for implementation in QC lot-release for potency testing, helping to accelerate the time-to-market for therapeutics by 6 to 9 months, and ensuring high lot-to-lot reproducibility and accuracy for the life of the program. These assays can be readily transferred and implemented in potency and stability programs that typically happen under GMP conditions at the sponsors’ testing sites or partner CRO/CDMO sites. Access off-the-shelf bioassay kits that have been successfully implemented in 100+ global programs covering popular and unique druggable target classes. NA = North America, EU = Europe, APAC = Asia Pacific, and NAb = Neutralizing Antibody.